A Study of Effectiveness and Safety of Risperdal CONSTA Added to Usual Treatment in Patients With Bipolar Disorder Who Have Frequent Mood Episodes.
Information source: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Bipolar Disorder
Intervention: Risperdal Consta (Drug); placebo (Drug)
Phase: Phase 3
Sponsored by: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Official(s) and/or principal investigator(s):
Johnson & Johnson Pharmaceutical Research and Development, L.L.C. Clinical Trial, Study Director, Affiliation: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
The purpose of this study is to examine the safety and effectiveness of the long acting
injectable form of the atypical antipsychotic Risperidone (Risperdal CONSTA), along with
treatment as usual (TAU), in bipolar disorder patients who had more than 4 mood episodes in
the past year.
Official title: A Prospective, Randomized, Double-Blind, Placebo-Controlled Study of the Effectiveness and Safety of RISPERDAL CONSTA Augmentation in Adult Patients With Frequently-Relapsing Bipolar Disorder
Study design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study
Primary outcome: Efficacy will be determined by measuring the time (in days) from randomization to event/relapse; relapse will be assessed by clinical status, rating scale changes, and pharmacologic stability in double-blind phase.
Secondary outcome: Safety and tolerability as assessed by adverse event reports (every 2 weeks), scores on movement disorder measures, laboratory parameters, vital signs, ECG measures and physical examination reports (every 2-3 months)
Frequently-relapsing (more than 4 episodes in the last year) bipolar patients are a sub-group
of patients who have multiple mood episodes in spite of treatment. Currently available
treatments may have little impact on number and frequency of manic and/or depressed mood
episodes and as a result, these patients have higher than average rates of illness and death.
This study examines the effectiveness and side effects of risperidone long-acting injections
(LAI) added to treatment as usual (TAU) in frequently-relapsing bipolar patients. The study
has two main phases. The first phase is open-label (patients and doctors know what medication
and dose the patient is receiving- both risperidone LAI and TAU) and lasts 16 weeks. During
that time, patients are treated with the goal that they reach "remission", a predefined level
of improvement (decrease in number and severity of mood episodes.) Patients who meet
remission criteria at the end of the first phase are randomized (like flipping a coin) to
either continue receiving the same dose of risperidone LAI plus TAU, or placebo injections
plus TAU. Patients continue in the second phase for 52 weeks, during which time the
effectiveness is measured by time to "relapse" (worsening of mood symptoms severe enough to
require hospitalization or a major change in medication.) Additional effectiveness, safety,
and side effect measures are evaluated throughout the length of the study.
Long-acting risperidone injection 25 mg will be administered every two weeks through a
gluteal injection for at least one month. Thereafter, the dose may be increased to 37. 5mg
then to 50 mg based on clinical response and tolerability. Supplemental use of oral Risperdal
(1 to 2 mg/day) will be permitted during the first 12 weeks of the Open-Label Stabilization
Phase. Patients must be taking a stable dose of risperidone LAI for the 4 weeks immediately
prior to entering the Double-Blind Phase.
Minimum age: 18 Years.
Maximum age: 70 Years.
- Must provide informed consent
- Must agree to receive regular injections
- Must have current diagnosis of bipolar disorder I or II
- Must have at least four episodes of mood disorder in the last year that required
- Female who is or may be pregnant or breastfeeding, who is not at least 1 year
postmenopausal, or is not using reliable and adequate birth control
- Psychiatric diagnosis is due directly to effects of a substance or general medical
- Substance dependence
- Received treatment with a long-acting injectable antipsychotic less than 2 injection
cycles prior to baseline (so, for example, if the drug is injected every 2 weeks, the
patient could not enroll in the study if they had received an injection within the
last 4 weeks)
- Received Electroconvulsive Therapy (ECT) within the last month
- Began psychotherapy ("talk therapy") within 2 months
- In the past month was treated with any of these medications: carbamazepine,
oxcarbazepine, fluoxetine, paroxetine, or clozapine
Locations and Contacts
Adjunctive Risperdal Consta Study in Frequently Relapsing Bipolar Disorder Patients
Starting date: May 2004
Ending date: February 2007
Last updated: March 17, 2008